AUG 17. FDA approvalThe greatest biotech stock story of this decade is about to hit the markets right now. To put it simply, one under-the-radar company is about to release a universal antidote that could likely save up to 1.5 million lives this year And every year after. When it does, it could add $1 billion to its revenues And send the stock soaring 8,233% over the long term possibly even higher every year, as many as 1.5 million people suffer from a severe medical event one that requires immediate attention. Worst of all, many of them are unable to beat this highly preventable cause of death One that has NOTHING to do with infection heart attacks or even human error. Most of these deaths are unrelated to the illness or condition that patients are being treated for. A miraculous new drug with an incredible patent moat and zero competition is on the brink of eliminating these untimely deaths once and for all